Home › Research › Disparities
Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial
Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, Fitzgerald S, Lockery JE et al.. JAMA psychiatry, 2020-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Importance Depression is associated with increased inflammation, which may precede its onset, especially in older people. Some preclinical data suggest potential antidepressant effects of aspirin, supported by limited observational data suggesting lower rates of depression in individuals treated with aspirin. There currently appears to be no evidence-based pharmacotherapies for the primary prevention of depression. Objective To determine whether low-dose aspirin (100 mg) reduces the risk of depression in healthy older adults. Design, setting, and participants This double-blinded, placebo-controlled randomized clinical trial was a substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, which examined if aspirin increased healthy life span, defined as survival free of dementia and disability. The prespecified secondary outcome was depression. Individuals of all races/ethnicities older than 70 years in Australia, as well as white individuals older than 70 years and black and Hispanic individuals older than 65 years in the United States, were included. Interventions Participants were randomized to aspirin (100 mg daily) or placebo, with a median (interquartile range) follow-up of 4.7 (3.5-5.6) years. Main outcomes and measures The primary outcome was a proxy measure of major depressive disorder defined as a score of 8 or more on the Center for Epidemiologic Studies Depression 10-item (CES-D-10) scale. Results Of the 19 114 participants enrolled in the trial, 9525 received aspirin and 9589 received a placebo. The mean (SD) age was 75.2 (4.0) years in the aspirin group and 75.1 (4.5) years in the placebo group; 9531 (56.4%) were women. Participants' demographics and clinical characteristics at baseline were similar between groups. A total of 79 886 annual CES-D-10 measurements were taken, with a mean of 4.2 measurements per participant. There were no significant differences at annual visits in the proportions of CES-D-10 scores of 8 or more between the aspirin and placebo groups. The incidence rate of new CES-D-10 scores of 8 or more was 70.4 events per 1000 person-years in the aspirin group and 69.1 in the placebo group (hazard ratio, 1.02 [95% CI, 0.96-1.08]; P = .54). Conclusions and relevance Low-dose aspirin did not prevent depression in this large-scale study of otherwise healthy older adults. Trial registration ClinicalTrials.gov Identifier: NCT01038583.
What this study adds
Evidence grade: High
This is a trial of 114 participants. This large randomized trial found no significant differences in the proportions of older adults with elevated depression scores between those taking low-dose aspirin and those taking placebo. Reported effect size: 56.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Berk, M., Woods, R. L., Nelson, M. R., Shah, R. C., Reid, C. M., Storey, E., et al. (2020). Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.1214
Vancouver
Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA psychiatry. 2020. doi:10.1001/jamapsychiatry.2020.1214. PMID: 32492080.
BibTeX
@article{berk2020-32492080,
author = {Berk, M. and Woods, R. L. and Nelson, M. R. and Shah, R. C. and Reid, C. M. and Storey, E. and Fitzgerald, S. and Lockery, J. E. and others},
title = {{Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial}},
journal = {JAMA psychiatry},
year = {2020},
doi = {10.1001/jamapsychiatry.2020.1214},
pmid = {32492080},
url = {https://doi.org/10.1001/jamapsychiatry.2020.1214}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Importance Depression is associated with increased inflammation, which may precede its onset, especially in older people.
- Results Of the 19 114 participants enrolled in the trial, 9525 received aspirin and 9589 received a placebo.
- There were no significant differences at annual visits in the proportions of CES-D-10 scores of 8 or more between the aspirin and placebo groups.
Why it matters
This large randomized trial found no significant differences in the proportions of older adults with elevated depression scores between those taking low-dose aspirin and those taking placebo. It tested aspirin for prevention of depression, not for treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Participants114
- Effect size56.4%
- Evidence strengthHigh
How this study scored 70/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA psychiatry) |
| Journal's citation record | 3 / 4 | JAMA Psychiatry: journal h-index 256 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 114 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 87 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.9 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 3 / 6 | Cited 6.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 38 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author John J. McNeil: h-index 91 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Melbourne: institution h-index 1,342 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32492080) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamapsychiatry.2020.1214
- PubMed: 32492080
- Original source →
- Free full text: JAMA Psychiatry →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.